Cytokinetics, Incorporated (CYTK) Business Profile

What it does

Cytokinetics is a biopharmaceutical company that discovers, develops and commercializes medicines aimed at changing how muscles work. Its research focuses on cardiovascular and neuromuscular diseases in which muscle performance is impaired. Founded in 1997, the company is headquartered in South San Francisco. Robert I. Blum is its chief executive officer.

Its first commercial medicine is MYQORZO, also known as aficamten. It is an oral treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy, or oHCM, a condition in which thickened heart muscle obstructs blood flow from the heart. MYQORZO inhibits a heart-muscle protein called cardiac myosin, reducing the force of contraction and the obstruction. The medicine became available for prescription in the United States in January 2026 and has also been approved in the European Union and China.

The U.S. approval includes a risk management program intended to address the risk of heart failure caused by reduced pumping function. Prescribing physicians have certification, monitoring and counseling obligations, and dispensing pharmacies face restrictions and qualification requirements.

Cytokinetics is also studying aficamten in non-obstructive HCM, where the heart muscle is thickened but blood flow is not obstructed. Other investigational medicines include omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for a subset of patients with heart failure with preserved ejection fraction. These candidates require further development and regulatory approval before they can be marketed for those uses.

How it makes money

Cytokinetics operates in one reportable segment. Its revenue has come from license and milestone arrangements and collaborations, while sales of MYQORZO began in the United States in the first quarter of 2026. The company earns product revenue when the medicine is sold; continued treatment can generate repeat sales, although prescribing, patient access and persistence affect demand.

In FY2025, license and milestone revenue was $79.4 million and collaboration revenue was $8.7 million. Total revenue in the third quarter of 2026 was $47.6 million.

MYQORZO net product revenue was $44.5 million in the third quarter of 2026, including $43.1 million in the United States and $1.4 million in Europe. The European amount included an initial inventory build in Germany. Collaboration revenue was $3.1 million in the same quarter. Cytokinetics has not provided a product price in these figures, and net product revenue is not the same as a list price.

Outside markets it serves directly, the company uses licensing arrangements. Sanofi holds rights to develop and commercialize aficamten in China and Taiwan, and Bayer has exclusive development and commercialization rights in Japan, subject to certain reserved development rights. Cytokinetics also has agreements that transfer portions of future product revenue to financing partners. For example, RPI ICAV is entitled to 4.5% of worldwide annual net sales of products containing aficamten up to $5.0 billion and 1% above $5.0 billion.

The company has historically funded operations through sources including equity sales, revenue-interest agreements and debt. It has generated significant operating losses and expects to rely increasingly on MYQORZO sales and financing to fund its activities.

Customers and how it sells

Cytokinetics sells MYQORZO for patients with symptomatic oHCM, with cardiologists and other healthcare providers responsible for prescribing it. The company targets disease-specific centers and healthcare professionals through a specialty sales force, supported by services for prescribers and patients. Those services can help patients navigate insurance coverage, financial assistance and treatment logistics.

Cytokinetics estimates that approximately 10,000 U.S. cardiologists diagnose and initiate treatment for HCM, across academic centers and community settings. By the third quarter of 2026, it had nearly 1,100 U.S. prescribers for MYQORZO. The company estimates that approximately 120,000 U.S. patients are eligible for oHCM treatment, of whom about 28,000 are treated with a cardiac myosin inhibitor.

The United States was the principal source of MYQORZO product revenue in the third quarter of 2026. Cytokinetics launched the medicine in Germany and expects to launch in the United Kingdom in the fourth quarter of 2026 and in additional countries in 2027. MYQORZO also has approvals in China and Canada. Sanofi is responsible for commercialization in China, while Bayer has development and commercialization rights in Japan. Access depends on coverage and reimbursement arrangements that can differ by payer and country.

Suppliers and costs

Cytokinetics has no manufacturing facilities of its own. It relies on contract manufacturers for raw materials, active pharmaceutical ingredients, finished drugs and packaging for both commercial and clinical supply. MYQORZO supply agreements cover manufacturers in Asia, North America and Europe, but individual arrangements rely on single sources. Key registered starting materials for aficamten are sourced from manufacturers in China.

The company is building safety stock and working to add alternative suppliers and manufacturing sites. It expects the dual-sourcing program to take several years to execute, obtain regulatory approvals and become operational. It also must supply aficamten to its partners for development and commercialization in China, Taiwan and Japan.

Research and development and commercial activities are major uses of cash. In the third quarter of 2026, research and development expenses were $99.3 million, while selling, general and administrative expenses were $113.1 million. The latter included external costs associated with the MYQORZO launch and personnel costs. Operating cash use was $510.0 million in 2025, largely for research and development and administrative support, including commercial readiness.

Competitive position

MYQORZO competes in oHCM with Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb, and with generic beta blockers and calcium channel blockers, which are considered first-line standard of care. Edgewise Therapeutics, Lexicon, Tenaya and Braveheart Bio (Hengrui) are conducting clinical trials for drugs that could compete if successfully commercialized. Cytokinetics says its ability to compete depends on factors including safety, efficacy, physician acceptance, supply, reimbursement and intellectual-property protection.

MYQORZO’s U.S. label permits dose titration as early as two weeks, with an echocardiogram assessment within 2 to 8 weeks after starting treatment and subsequent dose changes. In the MAPLE-HCM trial, aficamten met its primary endpoint against metoprolol, a beta blocker. Cytokinetics has submitted a supplemental application seeking to add the trial results to the U.S. label.

Our reading: Clinical evidence and an approved label provide a basis for differentiation, but their competitive strength remains uncertain against an established branded drug and generic first-line treatments. Our reading: Cytokinetics’ focused sales force and patient-support services can help it reach prescribers, but payer coverage, physician acceptance and the REMS program limit how much protection distribution alone provides.

If approved, omecamtiv mecarbil and ulacamten would also face established treatments and drug candidates under development. Companies named in those markets include Novartis, Merck, Bayer, AstraZeneca, Eli Lilly and Novo Nordisk.

Growth opportunities

Cytokinetics is seeking to expand MYQORZO use among eligible oHCM patients and enter additional geographic markets. It estimates that approximately 120,000 U.S. patients are eligible for oHCM treatment. Its five-year strategy includes a goal of reaching 100,000 patients globally with its medicines and achieving access and use in 15 countries across North America and Europe. Those are company goals, not established sales or patient counts.

A potential expansion of aficamten into non-obstructive HCM is another development objective. Cytokinetics says the Phase 3 ACACIA-HCM trial met both primary endpoints, with statistically significant improvements against placebo in patient-reported health status and exercise capacity. The company planned to submit a supplemental U.S. application in the fourth quarter of 2026 and a European application in early 2027. Any launch for that indication depends on regulatory approval.

Beyond aficamten, Cytokinetics is studying omecamtiv mecarbil in the Phase 3 COMET-HF trial for symptomatic heart failure with severely reduced ejection fraction. It is also enrolling patients in the Phase 2 AMBER-HFpEF study of ulacamten. The company expects COMET-HF enrollment to continue through 2027.

Earlier research includes muscle-related drug candidates and a collaboration focused on targeted protein degraders. Cytokinetics achieved a preclinical milestone in that collaboration. It also intends to expand its pipeline through internal research and external collaborations.

Structural risks

• Market acceptance and reimbursement: Physicians and patients may not adopt MYQORZO, and coverage or reimbursement may be delayed, inadequate or unavailable. Payers can also require rebates or patient payments that affect adoption or profitability.
• Safety and regulatory obligations: MYQORZO’s U.S. approval includes a REMS addressing heart-failure risk, with obligations for prescribers and dispensing pharmacies. Newly identified safety problems could lead to marketing restrictions or withdrawal.
• Manufacturing dependence: The company relies on single-source contract manufacturers for parts of MYQORZO supply. A shortage, compliance failure, trade restriction or difficulty qualifying a replacement site could interrupt supply or delay development.
• Clinical and approval uncertainty: Drug candidates and label expansions require successful trials and regulatory review. The FDA issued a complete response letter for omecamtiv mecarbil despite the earlier GALACTIC-HF trial meeting its primary efficacy endpoint.
• Competition and financing: MYQORZO faces an established branded competitor and generic therapies. Cytokinetics has generated significant operating losses and has used equity, debt and revenue-interest financing; payments on those arrangements and continued development and launch spending require cash.

Bottom line

Our reading

Cytokinetics is a muscle-focused drug developer transitioning into a commercial business around its first approved medicine, MYQORZO. [item1; call_prepared] Its future depends on expanding that launch while funding clinical programs and navigating reimbursement, safety requirements and single-source manufacturing. [item1; item1a; item7] The pipeline offers additional potential indications and medicines, but their commercial contribution depends on trial outcomes and regulatory approvals. [item1; facts]